AMG 386 Phase 2 Open-Label Renal Cell Carcinoma (RCC) Study 1st Line or After Cytokine Failure in Combination With Sunitinib

NCT00853372 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

85

Enrollment

INDUSTRY

Sponsor class

Conditions

Advanced Renal Cell Carcinoma

Interventions

DRUG: Sunitinib
DRUG: Trebananib

Sponsor

Amgen